(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual revenue growth rate of 17.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.41%.
Monte Rosa Therapeutics's revenue in 2025 is $75,622,000.On average, 3 Wall Street analysts forecast GLUE's revenue for 2025 to be $5,993,270,919, with the lowest GLUE revenue forecast at $4,785,464,074, and the highest GLUE revenue forecast at $7,043,489,603. On average, 3 Wall Street analysts forecast GLUE's revenue for 2026 to be $5,526,226,848, with the lowest GLUE revenue forecast at $1,230,196,420, and the highest GLUE revenue forecast at $10,564,926,855.
In 2027, GLUE is forecast to generate $8,385,018,799 in revenue, with the lowest revenue forecast at $922,647,315 and the highest revenue forecast at $15,847,390,282.